Detalhe da pesquisa
1.
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Acta Derm Venereol
; 104: adv18452, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38708991
2.
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
J Eur Acad Dermatol Venereol
; 38(2): 340-353, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37669868
3.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
J Am Acad Dermatol
; 89(3): 478-485, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230366
4.
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
J Am Acad Dermatol
; 89(3): 519-528, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37150299
5.
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
J Eur Acad Dermatol Venereol
; 37(12): 2558-2568, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37528500
6.
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
J Drugs Dermatol
; 22(4): 344-354, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37026893
7.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Lancet
; 397(10290): 2151-2168, 2021 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023008
8.
Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ).
Bipolar Disord
; 20(7): 594-603, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29869405
9.
Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Acta Derm Venereol
; 98(10): 932-937, 2018 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30085324
10.
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
J Dermatolog Treat
; 35(1): 2344589, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697950
11.
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Am J Clin Dermatol
; 25(3): 485-496, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38528257
12.
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Dermatol Ther (Heidelb)
; 14(5): 1127-1144, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38696027
13.
Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
Curr Med Res Opin
; 39(10): 1289-1296, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691437
14.
Patient preferences for atopic dermatitis treatments: a discrete choice experiment.
J Dermatolog Treat
; 34(1): 2222201, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37349865
15.
Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.
Dermatol Ther (Heidelb)
; 13(10): 2247-2264, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658223
16.
A patient-centred conceptual model of nocturnal scratch and its impact in atopic dermatitis: A mixed-methods study supporting the development of novel digital measurements.
Skin Health Dis
; 3(5): e262, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37799371
17.
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis.
Dermatitis
; 2023 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38108653
18.
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
JAMA Dermatol
; 159(5): 526-535, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37043227
19.
Contextualizing an expanded definition of health literacy among adolescents in the health care setting.
Health Educ Res
; 27(6): 961-74, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22623619
20.
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS).
Dermatol Ther (Heidelb)
; 12(12): 2817-2827, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36333616